Loading stock data…
$11.79+0.19 (+1.64%)
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally.
Amarin Corporation plc in the Healthcare sector is trading at $11.79 with a market capitalization of $304M. Wall Street consensus targets $12.50 (2 analysts), implying a +6.0% move over the next 12 months. The stock is currently near its 52-week low of $11.25, remaining 18.1% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $42.21M↓ | $45.13M↓ | $49.22M↓ | $49.67M↓ | $72.74M |
| Gross Profit | $14.99M↓ | $17.77M↓ | $23.17M↑ | $22.21M↓ | $50.36M |
| Operating Income | -$11.97M↓ | -$8.01M↓ | -$2.26M↓ | -$1.70M↓ | $6.77M |
| Net Income | -$7.65M↑ | -$10.51M↓ | -$1.22M↑ | -$7.74M↑ | -$14.14M |
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only ...